Tags

Type your tag names separated by a space and hit enter

The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients.
Nutr Metab Cardiovasc Dis. 2010 Jun; 20(5):326-31.NM

Abstract

BACKGROUND AND AIMS

Cardiovascular diseases are the major cause of mortality among diabetic patients. The concentration of malondialdehyde (MDA) and homocysteine is believed to play a role in cardiovascular diseases. Omega-3 fatty acid supplementation could be effective in some diabetes complications and in the control of the glycemic index. However, it may increase lipid peroxidation. The objective of this study was to determine the effect of omega-3 fatty acids on the concentration of homocysteine and MDA in diabetic patients.

METHODS AND RESULTS

A randomized double-blind, placebo-controlled clinical trial was conducted on 81 patients with type 2 diabetes. The patients were randomly assigned to either the treatment or control groups. Each subject received three capsules of omega-3 fatty acids or a placebo every day for a period of 2months. The two groups were similar in terms of body mass index and food intake. At the beginning of the study and after 2months of supplementation their levels of HbA(1)c, homocysteine, MDA, C-reactive protein (CRP), total cholesterol, LDL-cholesterol and fasting blood sugar (FBS) were determined. Due to omega-3 fatty acid supplementation, homocysteine was changed significantly in both treatment and control groups up to -3.10mumol/L and 0.10mumol/L respectively, and HbA(1)c decreased by 0.75% in the treatment group and increased by 0.26% in the control group. However, the changes in fasting blood sugar (FBS), malondialdehyde (MDA), C-reactive protein (CRP), total cholesterol and LDL-cholesterol levels were not significant.

CONCLUSION

The consumption of omega-3 fatty acid supplements (3g/day) for 2months decreases the levels of homocysteine in diabetic patients with no change in FBS, MDA and CRP levels.

Authors+Show Affiliations

Department of Nutrition and Biochemistry, School of Health, Tehran University of Medical Sciences, Tehran, Iran.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19540739

Citation

Pooya, Sh, et al. "The Efficacy of Omega-3 Fatty Acid Supplementation On Plasma Homocysteine and Malondialdehyde Levels of Type 2 Diabetic Patients." Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, vol. 20, no. 5, 2010, pp. 326-31.
Pooya Sh, Jalali MD, Jazayery AD, et al. The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2010;20(5):326-31.
Pooya, S. h., Jalali, M. D., Jazayery, A. D., Saedisomeolia, A., Eshraghian, M. R., & Toorang, F. (2010). The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, 20(5), 326-31. https://doi.org/10.1016/j.numecd.2009.04.002
Pooya Sh, et al. The Efficacy of Omega-3 Fatty Acid Supplementation On Plasma Homocysteine and Malondialdehyde Levels of Type 2 Diabetic Patients. Nutr Metab Cardiovasc Dis. 2010;20(5):326-31. PubMed PMID: 19540739.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients. AU - Pooya,Sh, AU - Jalali,M Djalali, AU - Jazayery,A Djazayery, AU - Saedisomeolia,A, AU - Eshraghian,M Reza, AU - Toorang,F, Y1 - 2009/06/21/ PY - 2008/07/22/received PY - 2009/02/25/revised PY - 2009/04/01/accepted PY - 2009/6/23/entrez PY - 2009/6/23/pubmed PY - 2010/9/21/medline SP - 326 EP - 31 JF - Nutrition, metabolism, and cardiovascular diseases : NMCD JO - Nutr Metab Cardiovasc Dis VL - 20 IS - 5 N2 - BACKGROUND AND AIMS: Cardiovascular diseases are the major cause of mortality among diabetic patients. The concentration of malondialdehyde (MDA) and homocysteine is believed to play a role in cardiovascular diseases. Omega-3 fatty acid supplementation could be effective in some diabetes complications and in the control of the glycemic index. However, it may increase lipid peroxidation. The objective of this study was to determine the effect of omega-3 fatty acids on the concentration of homocysteine and MDA in diabetic patients. METHODS AND RESULTS: A randomized double-blind, placebo-controlled clinical trial was conducted on 81 patients with type 2 diabetes. The patients were randomly assigned to either the treatment or control groups. Each subject received three capsules of omega-3 fatty acids or a placebo every day for a period of 2months. The two groups were similar in terms of body mass index and food intake. At the beginning of the study and after 2months of supplementation their levels of HbA(1)c, homocysteine, MDA, C-reactive protein (CRP), total cholesterol, LDL-cholesterol and fasting blood sugar (FBS) were determined. Due to omega-3 fatty acid supplementation, homocysteine was changed significantly in both treatment and control groups up to -3.10mumol/L and 0.10mumol/L respectively, and HbA(1)c decreased by 0.75% in the treatment group and increased by 0.26% in the control group. However, the changes in fasting blood sugar (FBS), malondialdehyde (MDA), C-reactive protein (CRP), total cholesterol and LDL-cholesterol levels were not significant. CONCLUSION: The consumption of omega-3 fatty acid supplements (3g/day) for 2months decreases the levels of homocysteine in diabetic patients with no change in FBS, MDA and CRP levels. SN - 1590-3729 UR - https://www.unboundmedicine.com/medline/citation/19540739/The_efficacy_of_omega_3_fatty_acid_supplementation_on_plasma_homocysteine_and_malondialdehyde_levels_of_type_2_diabetic_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0939-4753(09)00097-0 DB - PRIME DP - Unbound Medicine ER -